Safety of combination therapy with rituximab and etanercept for patients with rheumatoid arthritis
Norbert Blank, Regina Max, Martin Schiller, Steffen Briem and Hanns-Martin Lorenz SIR, Treatment of RA with rituximab (RTX) is established for patients with an inadequate response to anti-TNF-α therapy [1–3]. Previous RTX trials show an ACR-70 response in ∼15% of all patients after 24 weeks [2, 3]. Therefore, a significant fraction of RA patients cannot be treated sufficiently. Other trials showed that [...]